Herbas VPB

Print
EN | LT
Supplementary protection
LT - C-arilgliukozido SGLT2 inhibitoriai ir būdas
EN - C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND METHOD
SPC
(11) Number of the document C 1506211
(68) Number of the document 1506211
(21) Application number for Supplementary Protection Certificate PA 2013 008
(22) Date of filing the application 2013-04-03
(41) Date of publication of the application 2013-05-27
Date of publication of SPC 2014-01-27
(24) Date of coming into effect of SPC 2023-05-16
Applicant
(71) Bristol-Myers Squibb Company, Route 206 and Province Line Road P.O. Box 4000, Princeton NJ 08543-4000, US
Grantee
(73) AstraZeneca AB, ., SE-151 85, Södertälje, SE
Attorney or representative
(74) Marius JAKULIS - JASON, AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius, LT
Number, date and code of the country of origin of the first authorization to place the medicinal or plant protection product on the market within regional economic community
(93) EU/1/12/795/001 - EU/1/12/795/010, 2012-11-12
Calculated date of expiry of the SPC
(94) 2027-11-14
Name of the product protected by the basic patent
(95) Dapagliflozinum
Paediatric extension
Request filed SPC extension granted until Request refused
2022-10-04 2028-05-14
Last renewal fee
Payment date Validity (years) Amount
2025-04-23 3 347.00 EUR
Next renewal fee
2026-05-16
Legal status
SPC term extension granted
Last update date 2025-04-24